Oncology-focused digital health company Flatiron Health has entered into a strategic partnership with Massive Bio, a company specializing in helping cancer patients find and enroll in appropriate clinical trials.
Under this new alliance, Flatiron Health will utilize Massive Bio's extensive database on a per-study basis to identify patients who are not currently enrolled in clinical trials but live within proximity to trial sites. These identified patients will then be directed to Flatiron's research locations, where they can be onboarded as new patients and potentially enrolled in clinical trials using Flatiron's proprietary technology and consolidated patient identification services.
Flatiron Health, known for its oncology-focused health technology platform, offers solutions that optimize the clinical trial process, including site selection and patient eligibility identification. The company also provides electronic health record services and clinical decision support tools to healthcare providers. Meanwhile, Massive Bio leverages artificial intelligence to identify cancer patients eligible for specific clinical trials and connect them and their physicians with applicable research opportunities.
"Flatiron Health is excited to join forces with Massive Bio, combining expertise and resources to advance personalized treatment options for cancer patients," Michael Bierl, vice president of clinical research partnerships and general manager Europe at Flatiron Health, said in a statement. "By leveraging Massive Bio's robust network and database, we can continue to utilize our cutting-edge tools to empower sites to progress research, enhance workflows and efficiencies, accelerate clinical trace pace while ensuring diverse patient populations have access to life-changing treatments that might otherwise be out of reach."
Arturo Loaiza-Bonilla, cofounder and chief medical officer at Massive Bio, emphasized the company's patient-centric approach: "By pairing our AI-driven platform and concierge services with Flatiron Health's extensive research infrastructure, we can help physicians and care teams expedite trial enrollment, reduce disparities in access and improve outcomes for more patients."
This partnership follows several recent collaborative initiatives by Flatiron Health. In March, the company joined forces with the University of Colorado Cancer Center to reduce administrative burdens for researchers through Flatiron Clinical Pipe, which transfers clinical trial data directly from electronic health records to electronic data capture systems. That same month, Flatiron collaborated with NRG Oncology to implement Flatiron Clinical Pipe in a multicenter clinical trial.
In February, Flatiron partnered with Exact Sciences to increase clinical evidence generation for Exact's molecular residual disease test Oncodetect, focusing on gathering real-world evidence from community care settings typically underrepresented in clinical trials.
Earlier in January, DeepScribe partnered with Flatiron to integrate AI documentation capabilities into Flatiron's OncoEMR platform, becoming the first ambient AI solution partner for Flatiron Health.
Massive Bio has also shown significant growth, securing $9 million in financing in 2022, led by Revo Capital and Kenan Turnacioğlu, with participation from DEG. The company has used these funds to expand its global operations, enhance marketing efforts, and launch new products.
Click here for the original news story.